Pyruvate minimizes rtPA toxicity from in vitro oxygen-glucose deprivation and reoxygenation

Myoung Gwi Ryou, Gourav Roy Choudhury, Ali Winters, Luokun Xie, Robert T. Mallet, Shaohua Yang

Research output: Contribution to journalArticleResearchpeer-review

8 Citations (Scopus)

Abstract

Clinical application of recombinant tissue plasminogen activator (rtPA) for stroke is limited by hemorrhagic transformation, which narrows rtPA's therapeutic window. In addition, mounting evidence indicates that rtPA is potentially neurotoxic if it traverses a compromised blood brain barrier. Here, we demonstrated that pyruvate protects cultured HT22 neuronal and primary microvascular endothelial cells co-cultured with primary astrocytes from oxygen glucose deprivation (OGD)/reoxygenation stress and rtPA cytotoxicity. After 3 or 6 h OGD, cells were reoxygenated with 11 mmol/L glucose±pyruvate (8 mmol/L) and/or rtPA (10 μg/ml). Measured variables included cellular viability (calcein AM and annexin-V/propidium iodide), reactive oxygen species (ROS; mitosox red and 2′,7′-dichlorofluorescein diacetate), NADPH, NADP+ and ATP contents (spectrophotometry), matrix metalloproteinase-2 (MMP2) activities (gelatin zymography), and cellular contents of MMP2, tissue inhibitor of metalloproteinase-2 (TIMP2), and phosphor-activation of anti-apoptotic p70s6 kinase, Akt and Erk (immunoblot). Pyruvate prevented the loss of HT22 cells after 3 h OGD±rtPA. After 6 h OGD, rtPA sharply lowered cell viability; pyruvate dampened this effect. Three hours OGD and 4 h reoxygenation with rtPA increased ROS formation by about 50%. Pyruvate prevented this ROS formation and doubled cellular NADPH/NADP + ratio and ATP content. In endothelial cell monolayers, 3 h OGD and 24 h reoxygenation increased FITC-dextran leakage, indicating disruption of intercellular junctions. Although rtPA exacerbated this effect, pyruvate prevented it while sharply lowering MMP2/TIMP2 ratio and increasing phosphorylation of p70s6 kinase, Akt and Erk. Pyruvate protects neuronal cells and microvascular endothelium from hypoxia-reoxygenation and cytotoxic action of rtPA while reducing ROS and activating anti-apoptotic signaling. These results support the proposed use of pyruvate as an adjuvant to dampen the side effects of rtPA treatment, thereby extending rtPA's therapeutic window.

Original languageEnglish
Pages (from-to)66-75
Number of pages10
JournalBrain Research
Volume1530
DOIs
StatePublished - 12 Sep 2013

Fingerprint

Tissue Plasminogen Activator
Pyruvic Acid
Oxygen
Glucose
NADP
Matrix Metalloproteinase 2
Tissue Inhibitor of Metalloproteinase-2
Phosphotransferases
Endothelial Cells
Adenosine Triphosphate
In Vitro Techniques
Intercellular Junctions
Propidium
Spectrophotometry
Annexin A5
Gelatin
Blood-Brain Barrier
Astrocytes
Endothelium
Reactive Oxygen Species

Keywords

  • Antioxidant
  • Blood brain barrier
  • Cell death
  • Matrix metalloproteinases
  • Monocarboxylate transporter
  • Reactive oxygen species

Cite this

Ryou, Myoung Gwi ; Choudhury, Gourav Roy ; Winters, Ali ; Xie, Luokun ; Mallet, Robert T. ; Yang, Shaohua. / Pyruvate minimizes rtPA toxicity from in vitro oxygen-glucose deprivation and reoxygenation. In: Brain Research. 2013 ; Vol. 1530. pp. 66-75.
@article{8c36b17ce5f44bccb0f8235dbbd447fe,
title = "Pyruvate minimizes rtPA toxicity from in vitro oxygen-glucose deprivation and reoxygenation",
abstract = "Clinical application of recombinant tissue plasminogen activator (rtPA) for stroke is limited by hemorrhagic transformation, which narrows rtPA's therapeutic window. In addition, mounting evidence indicates that rtPA is potentially neurotoxic if it traverses a compromised blood brain barrier. Here, we demonstrated that pyruvate protects cultured HT22 neuronal and primary microvascular endothelial cells co-cultured with primary astrocytes from oxygen glucose deprivation (OGD)/reoxygenation stress and rtPA cytotoxicity. After 3 or 6 h OGD, cells were reoxygenated with 11 mmol/L glucose±pyruvate (8 mmol/L) and/or rtPA (10 μg/ml). Measured variables included cellular viability (calcein AM and annexin-V/propidium iodide), reactive oxygen species (ROS; mitosox red and 2′,7′-dichlorofluorescein diacetate), NADPH, NADP+ and ATP contents (spectrophotometry), matrix metalloproteinase-2 (MMP2) activities (gelatin zymography), and cellular contents of MMP2, tissue inhibitor of metalloproteinase-2 (TIMP2), and phosphor-activation of anti-apoptotic p70s6 kinase, Akt and Erk (immunoblot). Pyruvate prevented the loss of HT22 cells after 3 h OGD±rtPA. After 6 h OGD, rtPA sharply lowered cell viability; pyruvate dampened this effect. Three hours OGD and 4 h reoxygenation with rtPA increased ROS formation by about 50{\%}. Pyruvate prevented this ROS formation and doubled cellular NADPH/NADP + ratio and ATP content. In endothelial cell monolayers, 3 h OGD and 24 h reoxygenation increased FITC-dextran leakage, indicating disruption of intercellular junctions. Although rtPA exacerbated this effect, pyruvate prevented it while sharply lowering MMP2/TIMP2 ratio and increasing phosphorylation of p70s6 kinase, Akt and Erk. Pyruvate protects neuronal cells and microvascular endothelium from hypoxia-reoxygenation and cytotoxic action of rtPA while reducing ROS and activating anti-apoptotic signaling. These results support the proposed use of pyruvate as an adjuvant to dampen the side effects of rtPA treatment, thereby extending rtPA's therapeutic window.",
keywords = "Antioxidant, Blood brain barrier, Cell death, Matrix metalloproteinases, Monocarboxylate transporter, Reactive oxygen species",
author = "Ryou, {Myoung Gwi} and Choudhury, {Gourav Roy} and Ali Winters and Luokun Xie and Mallet, {Robert T.} and Shaohua Yang",
year = "2013",
month = "9",
day = "12",
doi = "10.1016/j.brainres.2013.07.029",
language = "English",
volume = "1530",
pages = "66--75",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",

}

Pyruvate minimizes rtPA toxicity from in vitro oxygen-glucose deprivation and reoxygenation. / Ryou, Myoung Gwi; Choudhury, Gourav Roy; Winters, Ali; Xie, Luokun; Mallet, Robert T.; Yang, Shaohua.

In: Brain Research, Vol. 1530, 12.09.2013, p. 66-75.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Pyruvate minimizes rtPA toxicity from in vitro oxygen-glucose deprivation and reoxygenation

AU - Ryou, Myoung Gwi

AU - Choudhury, Gourav Roy

AU - Winters, Ali

AU - Xie, Luokun

AU - Mallet, Robert T.

AU - Yang, Shaohua

PY - 2013/9/12

Y1 - 2013/9/12

N2 - Clinical application of recombinant tissue plasminogen activator (rtPA) for stroke is limited by hemorrhagic transformation, which narrows rtPA's therapeutic window. In addition, mounting evidence indicates that rtPA is potentially neurotoxic if it traverses a compromised blood brain barrier. Here, we demonstrated that pyruvate protects cultured HT22 neuronal and primary microvascular endothelial cells co-cultured with primary astrocytes from oxygen glucose deprivation (OGD)/reoxygenation stress and rtPA cytotoxicity. After 3 or 6 h OGD, cells were reoxygenated with 11 mmol/L glucose±pyruvate (8 mmol/L) and/or rtPA (10 μg/ml). Measured variables included cellular viability (calcein AM and annexin-V/propidium iodide), reactive oxygen species (ROS; mitosox red and 2′,7′-dichlorofluorescein diacetate), NADPH, NADP+ and ATP contents (spectrophotometry), matrix metalloproteinase-2 (MMP2) activities (gelatin zymography), and cellular contents of MMP2, tissue inhibitor of metalloproteinase-2 (TIMP2), and phosphor-activation of anti-apoptotic p70s6 kinase, Akt and Erk (immunoblot). Pyruvate prevented the loss of HT22 cells after 3 h OGD±rtPA. After 6 h OGD, rtPA sharply lowered cell viability; pyruvate dampened this effect. Three hours OGD and 4 h reoxygenation with rtPA increased ROS formation by about 50%. Pyruvate prevented this ROS formation and doubled cellular NADPH/NADP + ratio and ATP content. In endothelial cell monolayers, 3 h OGD and 24 h reoxygenation increased FITC-dextran leakage, indicating disruption of intercellular junctions. Although rtPA exacerbated this effect, pyruvate prevented it while sharply lowering MMP2/TIMP2 ratio and increasing phosphorylation of p70s6 kinase, Akt and Erk. Pyruvate protects neuronal cells and microvascular endothelium from hypoxia-reoxygenation and cytotoxic action of rtPA while reducing ROS and activating anti-apoptotic signaling. These results support the proposed use of pyruvate as an adjuvant to dampen the side effects of rtPA treatment, thereby extending rtPA's therapeutic window.

AB - Clinical application of recombinant tissue plasminogen activator (rtPA) for stroke is limited by hemorrhagic transformation, which narrows rtPA's therapeutic window. In addition, mounting evidence indicates that rtPA is potentially neurotoxic if it traverses a compromised blood brain barrier. Here, we demonstrated that pyruvate protects cultured HT22 neuronal and primary microvascular endothelial cells co-cultured with primary astrocytes from oxygen glucose deprivation (OGD)/reoxygenation stress and rtPA cytotoxicity. After 3 or 6 h OGD, cells were reoxygenated with 11 mmol/L glucose±pyruvate (8 mmol/L) and/or rtPA (10 μg/ml). Measured variables included cellular viability (calcein AM and annexin-V/propidium iodide), reactive oxygen species (ROS; mitosox red and 2′,7′-dichlorofluorescein diacetate), NADPH, NADP+ and ATP contents (spectrophotometry), matrix metalloproteinase-2 (MMP2) activities (gelatin zymography), and cellular contents of MMP2, tissue inhibitor of metalloproteinase-2 (TIMP2), and phosphor-activation of anti-apoptotic p70s6 kinase, Akt and Erk (immunoblot). Pyruvate prevented the loss of HT22 cells after 3 h OGD±rtPA. After 6 h OGD, rtPA sharply lowered cell viability; pyruvate dampened this effect. Three hours OGD and 4 h reoxygenation with rtPA increased ROS formation by about 50%. Pyruvate prevented this ROS formation and doubled cellular NADPH/NADP + ratio and ATP content. In endothelial cell monolayers, 3 h OGD and 24 h reoxygenation increased FITC-dextran leakage, indicating disruption of intercellular junctions. Although rtPA exacerbated this effect, pyruvate prevented it while sharply lowering MMP2/TIMP2 ratio and increasing phosphorylation of p70s6 kinase, Akt and Erk. Pyruvate protects neuronal cells and microvascular endothelium from hypoxia-reoxygenation and cytotoxic action of rtPA while reducing ROS and activating anti-apoptotic signaling. These results support the proposed use of pyruvate as an adjuvant to dampen the side effects of rtPA treatment, thereby extending rtPA's therapeutic window.

KW - Antioxidant

KW - Blood brain barrier

KW - Cell death

KW - Matrix metalloproteinases

KW - Monocarboxylate transporter

KW - Reactive oxygen species

UR - http://www.scopus.com/inward/record.url?scp=84883219366&partnerID=8YFLogxK

U2 - 10.1016/j.brainres.2013.07.029

DO - 10.1016/j.brainres.2013.07.029

M3 - Article

VL - 1530

SP - 66

EP - 75

JO - Brain Research

JF - Brain Research

SN - 0006-8993

ER -